Pharma's Richest Ride Demand Tailwinds
The stellar run continues post-Covid as promoters reap benefits of growth in India and new launches in key markets.
pharmaceuticals
September 2023
August 2023
January 2023
September 2022
February 2022
December 2021
October 2021
July 2021
Launching products in India at the same time as FDA approvals: Bayer
Bayer Pharmaceuticals positions India as a key supplier of raw materials and R&D support for global production.
Budget 2023 may offer Research Linked Incentive scheme for Indian pharma
RLI is expected to provide an extra financial cushion, in addition to the existing R&D sops available to pharmaceutical and biotech companies operating in India.
Surprise! Despite Covid-19 sales, Indian pharma an underperformer
A majority of pharma stocks reported double digit negative returns, while the overall market (BSE Sensex) delivered a 9% plus return.
Vaccines, Biologics: Indian Pharma’s New Temptations
API, diagnostics, New Chemical Entity — Covid has thrown up new opportunities, and domestic pharma biggies are charging in with renewed focus.
Predictions 2022: The pandemic and beyond: How the pharma industry is shaping up for the future
In the coming year, the pharma industry will continue to reimagine itself while driving growth and boosting value.
55 Indian pharma cos capable of mRNA vaccines
Almost every major Indian pharmaceutical company, including Cipla, Dr Reddy’s, Sun Pharma and Biocon, are on the list of companies which can produce mRNA Covid-19 vaccines
Piramal demerges pharma business, to list on stock exchanges
Restructuring to simplify corporate structure, create two separate listed entities.
Watch: Cipla on Covid and beyond
In the latest episode of Biz Buzz, Umang Vohra, global MD & CEO, Cipla, talks about the paradigm shift in the Indian pharma industry, and Cipla's plans for booster shots of Covid-19 vaccine.
Syngene’s winning formula
Syngene International was started by Biocon in 1993 to provide research services for pharma companies. Three decades later, the entity wants to become a global science company in its own right.
